PS13 - 6. DPP-4 inhibition as preventive strategy for the diabetogenic effects of glucocorticoids in men with the metabolic syndrome 鈥?a randomised controlled trial

详细信息    查看全文

• 作者：R.E. van Genugten ; D.H. van Raalte…
• 刊名：Nederlands Tijdschrift voor Diabetologie
• 出版年：2013
• 出版时间：November 2013
• 年：2013
• 卷：11
• 期：4
• 页码：194
• 全文大小：
• 作者单位：R.E. van Genugten (283)
  D.H. van Raalte (283)
  M.H. Muskiet (283)
  M.W. Heymans (284)
  P.J.W. Pouwels (285)
  D.M. Ouwens (286) (287)
  A. Mari (288)
  M. Diamant (283)
  
  283. Diabetes Centre, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands
  284. Department of Methodology and Applied Biostatistics, Institute of Health Sciences, VU University Medical Center, Amsterdam, The Netherlands
  285. Department of Physics and Medical Technology, VU University Medical Center, Amsterdam, The Netherlands
  286. Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Centre, D眉sseldorf, Germany
  287. Department of Endocrinology, Ghent University Hospital, Ghent, Belgium
  288. Institute of Biomedical Engineering, National Research Council, Padova, Italy
  
• 刊物类别：Diabetes;
• 刊物主题：Diabetes;
• 出版者：Bohn Stafleu van Loghum
• ISSN：1876-6242

文摘

Anti-inflammatory glucocorticoid therapy often induces hyperglycaemia due to insulin resistance and islet-cell dysfunction. Incretin-based therapies may preserve glucose tolerance and pancreatic islet-cell function. We hypothesised that concomitant administration of the DPP-4 inhibitor sitagliptin and prednisolone in men at high risk to develop type 2 diabetes, could protect against the glucocorticoid-induced diabetogenic effects. 1 Diabetes Centre, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands, 2 Department of Methodology and Applied Biostatistics, Institute of Health Sciences, VU University Medical Center, Amsterdam, The Netherlands, 3 Department of Physics and Medical Technology, VU University Medical Center, Amsterdam, The Netherlands, 4 Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Centre, D眉sseldorf, Germany, 5 Department of Endocrinology, Ghent University Hospital, Ghent, Belgium, 6 Institute of Biomedical Engineering, National Research Council, Padova, Italy